

# Duvuru Geetha

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1606620/publications.pdf>

Version: 2024-02-01

86  
papers

4,976  
citations

257450

24  
h-index

91884

69  
g-index

88  
all docs

88  
docs citations

88  
times ranked

3956  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2010, 363, 221-232.	27.0	2,275
2	Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2013, 369, 417-427.	27.0	611
3	ANCA-Associated Vasculitis: Core Curriculum 2020. <i>American Journal of Kidney Diseases</i> , 2020, 75, 124-137.	1.9	249
4	Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 976-985.	6.1	137
5	Bladder carcinoma in a transplant recipient: evidence to implicate the BK human polyomavirus as a causal transforming agent. <i>Transplantation</i> , 2002, 73, 1933-1936.	1.0	125
6	Pure red cell aplasia caused by Parvovirus B19 infection in solid organ transplant recipients: a case report and review of literature. <i>Clinical Transplantation</i> , 2000, 14, 586-591.	1.6	103
7	Incidence and Outcomes of BK Virus Allograft Nephropathy among ABO- and HLA-Incompatible Kidney Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1320-1327.	4.5	98
8	Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two-Dose SARS-CoV-2 Messenger RNA Vaccination. <i>Arthritis and Rheumatology</i> , 2022, 74, 28-32.	5.6	91
9	Renal Transplantation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Multicenter Experience. <i>Transplantation</i> , 2011, 91, 1370-1375.	1.0	71
10	Contraceptive Options for Women With a History of Solid-Organ Transplantation. <i>Transplantation</i> , 2013, 95, 1183-1186.	1.0	60
11	Ureteral Stents: A Novel Risk Factor for Polyomavirus Nephropathy. <i>Transplantation</i> , 2007, 84, 433-436.	1.0	54
12	Results of Repeat Renal Transplantation After Graft Loss From BK Virus Nephropathy. <i>Transplantation</i> , 2011, 92, 781-786.	1.0	47
13	Levamisole adulterated cocaine associated ANCA vasculitis: review of literature and update on pathogenesis. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2018, 8, 339-344.	0.8	47
14	Rituximab for remission induction in elderly patients with ANCA-associated vasculitis. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 67-69.	3.4	43
15	Antineutrophil Cytoplasmic Antibody Vasculitis Associated with Influenza Vaccination. <i>American Journal of Nephrology</i> , 2013, 38, 174-178.	3.1	42
16	Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Kidney International Reports</i> , 2018, 3, 1039-1049.	0.8	41
17	Validation of the new classification of pauci-immune glomerulonephritis in a United States cohort and its correlation with renal outcome. <i>BMC Nephrology</i> , 2013, 14, 210.	1.8	39
18	Characteristics and outcome of crescentic glomerulonephritis in patients with both antineutrophil cytoplasmic antibody and anti-glomerular basement membrane antibody. <i>Clinical Rheumatology</i> , 2013, 32, 1317-1322.	2.2	39

#	ARTICLE	IF	CITATIONS
19	Treatment of Severe Renal Disease in ANCA Positive and Negative Small Vessel Vasculitis with Rituximab. <i>American Journal of Nephrology</i> , 2015, 41, 296-301.	3.1	39
20	Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>CKJ: Clinical Kidney Journal</i> , 2017, 10, 470-474.	2.9	36
21	Renal Transplantation in the ANCA-Associated Vasculitides. <i>American Journal of Transplantation</i> , 2007, 7, 2657-2662.	4.7	34
22	Rituximab for treatment of severe renal disease in ANCA associated vasculitis. <i>Journal of Nephrology</i> , 2016, 29, 195-201.	2.0	33
23	Persistent or New Onset Microscopic Hematuria in Patients with Small Vessel Vasculitis in Remission: Findings on Renal Biopsy. <i>Journal of Rheumatology</i> , 2012, 39, 1413-1417.	2.0	27
24	Advances in Understanding of Pathogenesis and Treatment of Immune-Mediated Kidney Disease: A Review. <i>American Journal of Kidney Diseases</i> , 2022, 79, 582-600.	1.9	26
25	Rituximab for remission induction in recurrent ANCA-associated glomerulonephritis postkidney transplant. <i>Transplant International</i> , 2013, 26, 1225-1231.	1.6	25
26	Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1888-1893.	5.6	25
27	The COVID-19 pandemic and ANCA-associated vasculitis – reports from the EUVAS meeting and EUVAS education forum. <i>Autoimmunity Reviews</i> , 2021, 20, 102986.	5.8	25
28	A historical study of American patients with anti-neutrophil cytoplasmic antibody negative pauci-immune glomerulonephritis. <i>Clinical Rheumatology</i> , 2016, 35, 953-960.	2.2	23
29	The impact of COVID-19 pandemic on patients with ANCA associated vasculitis. <i>Journal of Nephrology</i> , 2021, 34, 185-190.	2.0	23
30	Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1400-1410.	0.7	21
31	Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab. <i>Journal of Nephrology</i> , 2015, 28, 17-27.	2.0	20
32	Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 301-308.	0.7	20
33	Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. <i>Rheumatology</i> , 2021, 60, 4654-4661.	1.9	20
34	Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’ by Bonelli <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e164-e164.	0.9	17
35	Hematuria duration does not predict kidney function at 1 year in ANCA-associated glomerulonephritis. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 198-201.	3.4	16
36	Relevance of ANCA positivity at the time of renal transplantation in ANCA associated vasculitis. <i>Journal of Nephrology</i> , 2017, 30, 147-153.	2.0	16

#	ARTICLE	IF	CITATIONS
37	Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. <i>American Journal of Nephrology</i> , 2017, 46, 231-238.	3.1	15
38	Timing of COVID-19 Vaccine in the Setting of Anti-CD20 Therapy: A Primer for Nephrologists. <i>Kidney International Reports</i> , 2021, 6, 1197-1199.	0.8	15
39	Outcomes of hydralazine induced renal vasculitis. <i>European Journal of Rheumatology</i> , 2018, 5, 5-8.	0.6	15
40	ANCA Status or Clinical Phenotype – What Counts More?. <i>Current Rheumatology Reports</i> , 2021, 23, 37.	4.7	14
41	Renal transplantation in anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2014, 30 Suppl 1, i159-63.	0.7	13
42	Older patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective study. <i>BMC Nephrology</i> , 2015, 16, 88.	1.8	13
43	Predictors of Renal Outcomes in Sclerotic Class Anti-Neutrophil Cytoplasmic Antibody Glomerulonephritis. <i>American Journal of Nephrology</i> , 2018, 48, 465-471.	3.1	13
44	Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Kidney International</i> , 2022, 101, 414-415.	5.2	13
45	Impact of rituximab on humoral response to COVID-19 booster vaccine and antibody kinetics in patients with anti-neutrophil cytoplasmic antibody vasculitis. <i>Kidney International</i> , 2021, 100, 1124-1127.	5.2	11
46	Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2190-2200.	0.7	11
47	Dapsone induced hemolysis in a patient with ANCA associated glomerulonephritis and normal G6PD level and implications for clinical practice: case report and review of the literature. <i>SpringerPlus</i> , 2015, 4, 29.	1.2	10
48	Characteristics and Outcomes of COVID-19 in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Kidney International Reports</i> , 2021, 6, 806-809.	0.8	10
49	Renal Transplant in Wegener's Granulomatosis Compared to Microscopic Polyangiitis. <i>Journal of Rheumatology</i> , 2010, 37, 1705-1708.	2.0	9
50	Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 778-783.	3.4	9
51	PEXIVAS challenges current ANCA-associated vasculitis therapy. <i>Nature Reviews Nephrology</i> , 2020, 16, 373-374.	9.6	9
52	Renal Transplantation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Current Perspectives. <i>Kidney and Blood Pressure Research</i> , 2020, 45, 157-165.	2.0	9
53	Clinical Characteristics of Hydralazine-induced Lupus. <i>Cureus</i> , 2019, 11, e4996.	0.5	9
54	Fibrillary Glomerulonephritis Presenting as Rapidly Progressive Glomerulonephritis. <i>American Journal of Kidney Diseases</i> , 2012, 60, 157-159.	1.9	8

#	ARTICLE	IF	CITATIONS
55	Clinical excellence in nephrology: Examples from the published literature. BMC Nephrology, 2015, 16, 141.	1.8	8
56	Crystal-storing histiocytosis. Kidney International, 2016, 89, 507.	5.2	8
57	Renal transplantation in anti-neutrophil cytoplasmic antibody vasculitis. Expert Review of Clinical Immunology, 2018, 14, 235-240.	3.0	8
58	Anti-glomerular basement membrane disease (Goodpasture disease): From pathogenesis to plasma exchange to IdeS. Therapeutic Apheresis and Dialysis, 2021, , .	0.9	8
59	ANCA Vasculitis Induction Management During the COVID-19 Pandemic. Kidney International Reports, 2021, 6, 2903-2907.	0.8	8
60	Immunotherapy for ANCA-associated vasculitis during the COVID-19 pandemic. European Journal of Rheumatology, 2020, 7, S121-S128.	0.6	8
61	Outcome of Renal Transplantation in Patients With Both ANCA and Anti-GBM Antibodies. Transplantation, 2012, 94, e30-e31.	1.0	7
62	Advances in Therapy for ANCA-Associated Vasculitis. Current Rheumatology Reports, 2012, 14, 509-515.	4.7	7
63	Treatment Outcomes of Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Patients Over Age 75 Years: A Meta-Analysis. American Journal of Nephrology, 2020, 51, 327-336.	3.1	7
64	ANCA-associated vasculitis in scleroderma: A renal perspective. Clinical Nephrology, 2018, 90, 413-418.	0.7	7
65	Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis. ImmunoTargets and Therapy, 2015, 4, 173.	5.8	6
66	Uncommon presentations in ANCA vasculitis: clinical characteristics and outcomes. Clinical Rheumatology, 2019, 38, 2195-2199.	2.2	6
67	Venous Thrombotic Events in ANCA-Associated Vasculitis: Incidence and Risk Factors. Kidney360, 2020, 1, 258-262.	2.1	6
68	Application of the ANCA Renal Risk Score in the United States: A Single-Center Experience. Kidney Medicine, 2021, 3, 686-688.	2.0	6
69	Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course. , 2022, 9, 93-99.		6
70	Renal involvement in primary Sjögren's syndrome: natural history and treatment outcome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 123-132.	0.8	6
71	Principles of Immunosuppression in the Management of Kidney Disease: Core Curriculum 2022. American Journal of Kidney Diseases, 2022, 80, 393-405.	1.9	6
72	Patient Outcomes in Renal-Limited Antineutrophil Cytoplasmic Antibody Vasculitis With Inactive Histology. Kidney International Reports, 2018, 3, 671-676.	0.8	5

#	ARTICLE	IF	CITATIONS
73	Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis. American Journal of Nephrology, 2019, 50, 386-391.	3.1	5
74	Long-term Clinical Course of Antineutrophil Cytoplasmic Antibody-associated Vasculitis Patients off Maintenance Therapy. Cureus, 2018, 10, e2372.	0.5	5
75	SARS-CoV-2 Vaccine Response in Patients With Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. Kidney International Reports, 2022, 7, 629-632.	0.8	5
76	Keeping Up with the Times. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1078-1080.	4.5	3
77	Polyomavirus-Associated Nephropathy. Medicine (United States), 2011, 90, 296-302.	1.0	2
78	Falling through the cracks of vasculitis classification—a report of three patients. CKJ: Clinical Kidney Journal, 2011, 4, 327-330.	2.9	2
79	Serum and urinary metabolites discriminate disease activity in ANCA associated glomerulonephritis in a pilot study. Journal of Nephrology, 2021, , 1.	2.0	2
80	Ranolazine-induced Elevation of Creatinine Kinase in the Absence of Statin Usage. Cureus, 2018, 10, e2832.	0.5	2
81	Bamlanivimab Decreases Severe Outcomes of SARS-CoV-2 Infection in Patients With Antineutrophil Cytoplasmic Antibody Vasculitis. Kidney International Reports, 2022, 7, 651-652.	0.8	2
82	Subcutaneous Immunoglobulin for Antibody Deficiency in Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis. Cureus, 2019, 11, e6367.	0.5	1
83	Characterization of interstitial infiltrates in MPO and PR3 anti-neutrophil cytoplasmic antibody glomerulonephritis. Journal of Nephrology, 2021, , 1.	2.0	0
84	An unusual complication of peritoneal dialysis. Cleveland Clinic Journal of Medicine, 2018, 85, 352-354.	1.3	0
85	Additional Refinement of CKD Prognostication Using Lymphatic Vessel Density: IgA Nephropathy as the Role Model?. Kidney International Reports, 2022, 7, 667-670.	0.8	0
86	The devil is in the details: Approach to refractory hypokalemia. Cleveland Clinic Journal of Medicine, 2022, 89, 182-188.	1.3	0